Ace inhibitors vs arbs
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Comparative Analysis of ACE Inhibitors vs. ARBs
Introduction to ACE Inhibitors and ARBs
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are widely used medications for managing hypertension and other cardiovascular conditions. Both drug classes target the renin-angiotensin system but through different mechanisms. ACE inhibitors block the conversion of angiotensin I to angiotensin II, while ARBs block the receptors for angiotensin II. This article synthesizes current research comparing the effectiveness, safety, and specific applications of ACE inhibitors and ARBs.
Effectiveness in Hypertension Management
Blood Pressure Control
Multiple studies have shown that ACE inhibitors and ARBs are equally effective in lowering blood pressure in patients with essential hypertension. A systematic review concluded that both drug classes have similar long-term effects on blood pressure control . This equivalence in efficacy makes both options viable first-line treatments for hypertension.
Cardiovascular Outcomes
When it comes to cardiovascular outcomes, such as the risk of myocardial infarction, heart failure, and stroke, ACE inhibitors and ARBs show no significant differences. A large-scale observational study found no statistically significant difference in the primary outcomes of acute myocardial infarction, heart failure, stroke, or composite cardiovascular events between the two drug classes. This suggests that either medication can be chosen based on patient-specific factors and preferences.
Safety Profile
Side Effects
One of the key differences between ACE inhibitors and ARBs lies in their side effect profiles. ACE inhibitors are more commonly associated with a persistent cough and angioedema. In contrast, ARBs have a better safety profile with a lower incidence of these side effects . This makes ARBs a preferable option for patients who experience adverse reactions to ACE inhibitors.
Risk of Pneumonia
Interestingly, ACE inhibitors have been associated with a reduced risk of pneumonia compared to ARBs. A meta-analysis indicated that ACE inhibitors might offer a protective effect against pneumonia, particularly in patients with a history of stroke and among Asian populations. This could be a consideration in choosing between the two medications for certain patient groups.
Special Populations
Chronic Kidney Disease (CKD)
In patients with chronic kidney disease (CKD), both ACE inhibitors and ARBs reduce the risk of kidney failure and major cardiovascular events. However, ACE inhibitors may have a slight edge in reducing all-cause mortality compared to ARBs. This suggests that ACE inhibitors might be the preferred choice for CKD patients, although both drug classes are beneficial.
Black Hypertensive Patients
The efficacy of ACE inhibitors and ARBs in black hypertensive patients has been debated. Some studies suggest that black patients may have a reduced blood pressure response to these medications compared to white patients. However, when used in combination with other antihypertensive agents like calcium channel blockers or thiazide diuretics, the efficacy is comparable. This highlights the importance of combination therapy in this population.
Impact on COVID-19 Outcomes
During the COVID-19 pandemic, concerns were raised about the safety of ACE inhibitors and ARBs due to their potential impact on ACE2 expression, the receptor for SARS-CoV-2. However, a meta-analysis and literature review found no evidence that these medications increase the risk of severe or lethal COVID-19. Patients on ACE inhibitors or ARBs did not show a higher risk of severe COVID-19 outcomes compared to untreated subjects . This supports the continued use of these medications during the pandemic.
Conclusion
Both ACE inhibitors and ARBs are effective and safe options for managing hypertension and other cardiovascular conditions. While they share similar efficacy in blood pressure control and cardiovascular outcomes, ARBs have a better safety profile with fewer side effects. Special populations, such as those with CKD or black hypertensive patients, may benefit from tailored treatment strategies. Current evidence also supports the continued use of these medications during the COVID-19 pandemic. Ultimately, the choice between ACE inhibitors and ARBs should be individualized based on patient-specific factors and clinical judgment.
Sources and full results
Most relevant research papers on this topic